Sökning: WFRF:(Mariani Maurizio F.) > Impact of liver tum...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08711naa a2200949 4500 | |
001 | oai:DiVA.org:uu-423870 | |
003 | SwePub | |
008 | 201110s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4238702 URI |
024 | 7 | a https://doi.org/10.1007/s00259-020-04709-x2 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Strosberg, Jonathanu H Lee Moffitt Canc Ctr & Res Inst, Neuroendocrine Tumor Div, Gastrointestinal Dept, Tampa, FL 33612 USA.4 aut |
245 | 1 0 | a Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate :b an analysis of the NETTER-1 study |
264 | c 2020-03-02 | |
264 | 1 | b SPRINGER,c 2020 |
338 | a electronic2 rdacarrier | |
520 | a Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate. Methods In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results Significantly prolonged median PFS occurred with Lu-177-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the Lu-177-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions Lu-177-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. : NCT01578239, EudraCT: 2011-005049-11 | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
653 | a Lu-177-Dotatate | |
653 | a Liver tumour burden | |
653 | a NETTER-1 | |
653 | a Neuroendocrine tumour | |
653 | a Octreotide | |
700 | 1 | a Kunz, Pamela L.u Stanford Univ, Med Ctr, Dept Med Med Oncol, Stanford, CA 94305 USA.4 aut |
700 | 1 | a Hendifar, Andrewu Cedars Sinai Med Ctr, Dept Internal Med Hematol Oncol, Los Angeles, CA 90048 USA.4 aut |
700 | 1 | a Yao, Jamesu Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.4 aut |
700 | 1 | a Bushnell, Davidu Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.4 aut |
700 | 1 | a Kulke, Matthew H.u Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.4 aut |
700 | 1 | a Baum, Richard P.u Zent Klin Bad Berka, Dept Nucl Med, Bad Berka, Germany.4 aut |
700 | 1 | a Caplin, Martynu Royal Free Hosp, Dept Gastroenterol & Tumour Neuroendocrinol, London, England.4 aut |
700 | 1 | a Ruszniewski, Philippeu Hop Beaujon, Div Gastroenterol & Pancreatol, Clichy, France.4 aut |
700 | 1 | a Delpassand, Ebrahimu Excel Diagnost Imaging Clin, Dept Clin Nucl Med, Houston, TX USA.4 aut |
700 | 1 | a Hobday, Timothyu Mayo Clin, Coll Med, Dept Oncol, Rochester, MN USA.4 aut |
700 | 1 | a Verslype, Chrisu Univ Hosp, Dept Hepatol, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium.4 aut |
700 | 1 | a Benson, Alu Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL USA.4 aut |
700 | 1 | a Srirajaskanthan, Rajaventhanu Kings Coll Hosp NHS Fdn Trust, Dept Gastroenterol & Gen Internal Med, London, England.4 aut |
700 | 1 | a Pavel, Marianneu Charite Univ Med Berlin, Div Gastroenterol & Hepatol, Berlin, Germany.4 aut |
700 | 1 | a Mora, Jaumeu Hosp Univ Bellvitge, Dept Nucl Med, Barcelona, Spain.4 aut |
700 | 1 | a Berlin, Jordanu Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.4 aut |
700 | 1 | a Grande, Enriqueu MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain.4 aut |
700 | 1 | a Reed, Nicholasu Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland.4 aut |
700 | 1 | a Seregni, Ettoreu Ist Nazl Tumori, Fdn Ist Ric & Cura Carattere Sci, Dept Nucl Med Therapy & Endocrinol, Milan, Italy.4 aut |
700 | 1 | a Paganelli, Giovanniu IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy.4 aut |
700 | 1 | a Severi, Stefanou IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy.4 aut |
700 | 1 | a Morse, Michaelu Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.4 aut |
700 | 1 | a Metz, David C.u Hosp Univ Penn, GI Div, 3400 Spruce St, Philadelphia, PA 19104 USA.4 aut |
700 | 1 | a Ansquer, Catherineu Univ Hosp, Hotel Dieu, Dept Nucl Med, Nantes, France.4 aut |
700 | 1 | a Courbon, Fredericu Oncol Univ, Inst Claudius Regaud, Med Imaging, Toulouse, France.4 aut |
700 | 1 | a Al-Nahhas, Adilu Imperial Coll London, Div Imaging & Intervent Radiol, London, England.4 aut |
700 | 1 | a Baudin, Ericu Inst Gustave Roussy, Dept Endocrine Oncol & Nucl Med, Villejuif, France.4 aut |
700 | 1 | a Giammarile, Francescou IAEA, Dept Nucl Sci & Applicat, Vienna, Austria.4 aut |
700 | 1 | a Taieb, Davidu Hop La Timone, Dept Nucl Med, Marseille, France.4 aut |
700 | 1 | a Mittra, Eriku Oregon Hlth & Sci Univ, Dept Nucl Med, Portland, OR 97201 USA.4 aut |
700 | 1 | a Wolin, Edwardu Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA.4 aut |
700 | 1 | a O'Dorisio, Thomas M.u Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.4 aut |
700 | 1 | a Lebtahi, Rachidau Royal Free Hosp, Dept Nucl Med, London, England.4 aut |
700 | 1 | a Deroose, Christophe M.u Univ Hosp, Dept Nucl Med, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium.4 aut |
700 | 1 | a Grana, Chiara M.u Ist Europeo Oncol, Div Nucl Med, Milan, Italy.4 aut |
700 | 1 | a Bodei, Lisau Mem Sloan Kettering Canc Ctr, Dept Nucl Med, 1275 York Ave, New York, NY 10021 USA.4 aut |
700 | 1 | a Öberg, Kjell,d 1946-u Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob |
700 | 1 | a Polack, Berna Degirmenciu Adv Accelerator Applicat, Dept Med Informat, Geneva, Switzerland.4 aut |
700 | 1 | a He, Beileiu Adv Accelerator Applicat, Geneva, Switzerland.4 aut |
700 | 1 | a Mariani, Maurizio F.u Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut |
700 | 1 | a Gericke, Germou Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut |
700 | 1 | a Santoro, Paolau Adv Accelerator Applicat, Dept Clin Dev, Geneva, Switzerland.4 aut |
700 | 1 | a Erion, Jack L.u Adv Accelerator Applicat, Geneva, Switzerland.4 aut |
700 | 1 | a Ravasi, Laurau Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut |
700 | 1 | a Krenning, Ericu Erasmus Univ, Med Ctr, Cyclotron Rotterdam BV, Dept Nucl Med, Rotterdam, Netherlands.4 aut |
710 | 2 | a H Lee Moffitt Canc Ctr & Res Inst, Neuroendocrine Tumor Div, Gastrointestinal Dept, Tampa, FL 33612 USA.b Stanford Univ, Med Ctr, Dept Med Med Oncol, Stanford, CA 94305 USA.4 org |
773 | 0 | t European Journal of Nuclear Medicine and Molecular Imagingd : SPRINGERg 47:10, s. 2372-2382q 47:10<2372-2382x 1619-7070x 1619-7089 |
856 | 4 | u https://doi.org/10.1007/s00259-020-04709-xy Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1499957/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://link.springer.com/content/pdf/10.1007/s00259-020-04709-x.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423870 |
856 | 4 8 | u https://doi.org/10.1007/s00259-020-04709-x |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy